Journal of Targeted Oncology Research

Dr. Amir Ali Hamidieh, M.D. is a Professor of Pediatric Hematology, Oncology, and Stem Cell Transplantation at Tehran University of Medical Sciences (TUMS), where he also serves as the Head of the Pediatric Hematology/Oncology and Stem Cell Transplantation Department at the Children’s Medical Center. As one of the leading figures in pediatric stem cell transplantation and cell and gene therapy in Iran, he has played a foundational role in establishing several national and institutional programs that advance regenerative medicine, immunotherapy, and pediatric transplant care.

Dr. Hamidieh is the Founder and Director of the Pediatric Cell & Gene Therapy Research Center, the Pediatric Stem Cell Transplantation Program, and the Innovation Center for Stem Cell and Regenerative Medicine at TUMS. He is also the Director of the Gene, Cell & Tissue Institute and has held key leadership positions within national science and research councils, including serving as Secretary General of the National Council for Development of Stem Cell Sciences and Technologies.

Internationally, Dr. Hamidieh is an active member of major global transplant and hematology networks. He has served on the Executive Board of the Asia Pacific Blood and Marrow Transplantation Group (APBMT), contributed to the Worldwide Network for Blood & Marrow Transplantation (WBMT), and participated in committees within the European Society for Blood and Marrow Transplantation (EBMT). His scientific services include membership on multiple journal editorial boards and extensive peer-review activity for high-impact journals in hematology, oncology, and transplantation.

His research spans a wide range of topics, including hematopoietic stem cell transplantation, CAR-T and CAR-NK cell therapy, immunotherapy for pediatric cancers, regenerative medicine, HLA and donor selection, primary immunodeficiencies, gene editing technologies, and artificial intelligence applications in transplant outcome prediction. Dr. Hamidieh has authored more than 100 peer-reviewed publications and led numerous clinical and translational research projects in pediatric oncology and stem cell therapy.

Through his clinical innovation, research leadership, and commitment to scientific development, Dr. Hamidieh has significantly contributed to advancing pediatric hematology and cellular therapeutics in Iran and the broader Asia-Pacific region.